WO2020084347A3 - Combination of a kinase inhibitor and an immunotherapeutic agent, compositions and methods comprising the same - Google Patents

Combination of a kinase inhibitor and an immunotherapeutic agent, compositions and methods comprising the same Download PDF

Info

Publication number
WO2020084347A3
WO2020084347A3 PCT/IB2019/001146 IB2019001146W WO2020084347A3 WO 2020084347 A3 WO2020084347 A3 WO 2020084347A3 IB 2019001146 W IB2019001146 W IB 2019001146W WO 2020084347 A3 WO2020084347 A3 WO 2020084347A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
same
kinase inhibitor
compositions
immunotherapeutic agent
Prior art date
Application number
PCT/IB2019/001146
Other languages
French (fr)
Other versions
WO2020084347A2 (en
Inventor
Adam Vorn Patterson
Ian Francis Hermans
Jeffrey Bruce SMIALL
Zhe FU
Original Assignee
Auckland Uniservices
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices filed Critical Auckland Uniservices
Publication of WO2020084347A2 publication Critical patent/WO2020084347A2/en
Publication of WO2020084347A3 publication Critical patent/WO2020084347A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed herein are combinations comprising a tyrosine kinase inhibitor (TKI) and an immunotherapeutic agent, formulations, and methods of treating cancer comprising the same.
PCT/IB2019/001146 2018-10-26 2019-10-25 Combination of a kinase inhibitor and an immunotherapeutic agent, compositions and methods comprising the same WO2020084347A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862751355P 2018-10-26 2018-10-26
US62/751,355 2018-10-26

Publications (2)

Publication Number Publication Date
WO2020084347A2 WO2020084347A2 (en) 2020-04-30
WO2020084347A3 true WO2020084347A3 (en) 2020-06-04

Family

ID=70331769

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/001146 WO2020084347A2 (en) 2018-10-26 2019-10-25 Combination of a kinase inhibitor and an immunotherapeutic agent, compositions and methods comprising the same

Country Status (1)

Country Link
WO (1) WO2020084347A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016090174A1 (en) * 2014-12-03 2016-06-09 Auckland Uniservices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
US20160166685A1 (en) * 2014-11-17 2016-06-16 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
WO2017173360A2 (en) * 2016-03-31 2017-10-05 Stcube, Inc. Combination treatments directed toward programmed death ligand-1 (pd-l1) positive cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160166685A1 (en) * 2014-11-17 2016-06-16 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
WO2016090174A1 (en) * 2014-12-03 2016-06-09 Auckland Uniservices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
WO2017173360A2 (en) * 2016-03-31 2017-10-05 Stcube, Inc. Combination treatments directed toward programmed death ligand-1 (pd-l1) positive cancers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AHN ET AL.: "EGFR TKI combination with immunotherapy in non-small cell lung cancer", EXPERT OPINION ON DRUG SAFETY, vol. 16, no. 4, 8 March 2017 (2017-03-08), pages 465 - 469, XP055714038 *

Also Published As

Publication number Publication date
WO2020084347A2 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
WO2020243415A3 (en) Tead inhibitors and uses thereof
PH12020551847A1 (en) Rip1 inhibitory compounds and methods for making and using the same
MX2022002718A (en) Rip1 inhibitory compounds and methods for making and using the same.
MX2023008031A (en) Gcn2 inhibitors and uses thereof.
MX2021014441A (en) Tead inhibitors and uses thereof.
PH12020551848A1 (en) Rip1 inhibitory compounds and methods for making and using the same
MX2020007799A (en) Gcn2 inhibitors and uses thereof.
CR20220075A (en) Rip1 inhibitory compounds and methods for making and using the same
WO2021127283A3 (en) Irak degraders and uses thereof
WO2017136450A3 (en) Compounds and methods of treating rna-mediated diseases
MX2021006674A (en) Compositions for stabilizing bacteria and uses thereof.
EP3856742A4 (en) Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof
WO2021055577A3 (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
WO2020033019A3 (en) Novel mct4 inhibitors and uses thereof
WO2020055643A3 (en) Compounds, compositions and methods for treating or preventing her-driven cancers
MX2020013170A (en) Agricultural composition.
CN112584841A8 (en) Tumor reduction formulations and methods of use thereof
IL288864A (en) Treatment comprising sglt inhibitors, e.g. sglt 1/2 inhibitors
ZA202106519B (en) Caspase inhibitors and methods of use thereof
WO2021113690A9 (en) Masp-2 inhibitors and methods of use
MX2022007988A (en) Crystalline forms of (s) -1- (1-acryloylpyrrolidin-3-yl) -3- ( (3, 5-dimethoxyphenyl) ethynyl) -5- (methylamino) -1h-pyrazole-4-carboxamide.
MX2022006312A (en) Ahr inhibitors and uses thereof.
EP4081033A4 (en) An adjuvant composition and the agricultural composition comprising the same
WO2020084347A3 (en) Combination of a kinase inhibitor and an immunotherapeutic agent, compositions and methods comprising the same
WO2019161004A3 (en) Radiopaque and echogenic coatings for medical devices

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19877526

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19877526

Country of ref document: EP

Kind code of ref document: A2